Goldman Sachs released a report, adjusting down the target price of medical-related stocks across the board by an average of about 9% before the second quarter and first half of the performance season. At the same time, the estimated industry sales for fiscal years 2024 to 2025 were adjusted down by 1% to 15% and 1% to 16%. The bank believes that investors will continue to pay attention to the potential impact of anti-medical corruption, updates to recent bulk procurement policies, and the replacement plan.

Goldman Sachs' investment ratings and target prices for pharmaceutical stocks are as follows:

Stock | Investment Rating | Target Price (HKD)

Weigao Group (01066.HK) | Buy | HKD 8.7 -> HKD 7.8

Kangji Medical (09997.HK) | Buy | HKD 11.2 -> HKD 10.6

AK Medical (01789.HK) | Buy | HKD 8.9 -> HKD 8.2

Hygeia Health (06078.HK) | Buy | HKD 50 -> HKD 46

Mindray Medical International (06609.HK) | Buy | HKD 29.8 -> HKD 25.6

KPC Pharmaceuticals Inc. (02273.HK) | Buy | HKD 61 -> HKD 60

Micro-TechEndoscopy (Holdings) Limited (02235.HK) | Sell | HKD 5.7 -> HKD 5

JXR (01951.HK) | Neutral | HKD 3.39 -> HKD 3.2

Chindex Medical (02500.HK) | Neutral | HKD 6 -> HKD 5.6